ID   RPK-59
AC   CVCL_0B32
SY   RPK59
DR   BTO; BTO:0005471
DR   cancercelllines; CVCL_0B32
DR   GEO; GSM862573
DR   GEO; GSM862575
DR   Wikidata; Q54951155
RX   PubMed=22490663;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22490663).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3850; Pancreatic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4897 ! PK-59
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 12
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//